Cc1 antigen retrieval solution

Manufactured by Roche

Sourced in United States

The CC1 antigen retrieval solution is a laboratory reagent used to prepare tissue samples for immunohistochemical analysis. Its core function is to facilitate the exposure of target antigens within the tissue samples, which is a necessary step in the immunohistochemistry process.

Automatically generated - may contain errors

Lab products found in correlation

Optiview amplification kit, by Roche (2 mentions) Dab detection system, by Roche (1 mentions) Haematoxylin and bluing reagent, by Roche (1 mentions) Optiview dab ihc kit, by Roche (1 mentions) Benchmark ultra, by Roche (1 mentions) Anti pd l1 clone 22c3, by Merck Group (1 mentions) Ventana benchmark ultra, by Roche (1 mentions) Ultraview dab, by Roche (1 mentions) Hematoxylin 2, by Roche (1 mentions)

3 protocols using cc1 antigen retrieval solution

Quantification of CD4+ and CD8+ TILs in TNBC

Check if the same lab product or an alternative is used in the 5 most similar protocols

The expression of CD4 and CD8 was determined in formalin-fixed paraffin-embedded tumor sections (4 µm) of TNBC patients using antibodies against human CD4 (#ACI3148A) and human CD8 (#CRM311A) (both from Biocare Medical, Pacheco, CA, USA), which are widely used in the clinic. Tonsils were used as positive controls for staining. CC1 antigen retrieval solution (Ventana, Oro Valley, AZ, USA) was used for heat-induced antigen retrieval in alkaline conditions. Staining patterns were detected using a DAB detection system (Ventana).
The determination of staining patterns was performed using a certified breast pathologist of the Sheba Medical Center in a blind manner. H&E staining was used to assess the tumor histology and identify leukocytes. Stained CD4+ TILs and CD8+ TILs were envisioned in high power field (HPF) view (400×). Data were presented as percentages of CD4+ TILs and CD8+ TILs out of total leukocytes in each specimen. Statistical analyses were performed using two-tailed unpaired Student’s t-tests. Values of p ≤ 0.05 were considered statistically significant.

Baram T., Erlichman N., Dadiani M., Balint-Lahat N., Pavlovski A., Meshel T., Morzaev-Sulzbach D., Gal-Yam E.N., Barshack I, & Ben-Baruch A. (2021). Chemotherapy Shifts the Balance in Favor of CD8+ TNFR2+ TILs in Triple-Negative Breast Tumors. Cells, 10(6), 1429.

+ Open protocol

+ Expand

Immunohistochemical Evaluation of PD-L1 Expression

Check if the same lab product or an alternative is used in the 5 most similar protocols

Four µm sections were cut from FFPE tissue blocks. After deparaffinization, antigen retrieval was performed by CC1 antigen retrieval solution (pH 8.0, Ventana Medical systems, Tuczon, AZ, USA) on the Ventana BenchMark Ultra automated slide stainer. Slides were incubated with the primary PD-L1 antibody (anti-PD-L1, clone 22C3, Merck) at a dilution of 1/100 for 32 min, followed by visualization with the OptiView DAB IHC Kit and OptiView Amplification Kit (Ventana Medical systems). The specimens were then counterstained with haematoxylin and bluing reagent (Ventana Medical systems) and coverslipped.
PD-L1 expression was scored in immune cells in the paracortex and in the sinuses of the lymph node, excluding the germinal centers. Similar to IDO1 scoring, the intensity of PD-L1 staining in the paracortex was evaluated according to a four-tiered grading system (Supplementary Figure 3A): no expression (0), weak expression (1+), moderate expression (2+) or strong expression (3+). PD-L1 expression in the paracortex was dichotomized into an PD-L1-low group (0 and 1+) and an PD-L1-high group (2+ and 3+). In the sinuses, PD-L1 staining was scored as ‘low’ or ‘high’ (Supplementary Figure 3B).

Meireson A., Ferdinande L., Haspeslagh M., Hennart B., Allorge D., Ost P., Sundahl N., Spaas M., Demeyer A, & Brochez L. (2021). Clinical Relevance of Serum Kyn/Trp Ratio and Basal and IFNγ-Upregulated IDO1 Expression in Peripheral Monocytes in Early Stage Melanoma. Frontiers in Immunology, 12, 736498.

+ Open protocol

+ Expand

Immunohistochemical Staining Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

The tumor material was processed by the pathology laboratory at the Erasmus MC according to routine procedures. A 4-μm section of formalin-fixed, paraffin-embedded tissue was mounted serially on adhesive glass slides. Deparaffinization was performed according to the Ventana BenchMark Ultra protocol. Antigen retrieval was performed by CC1 antigen retrieval solution (referent [ref.] 950-124, Ventana Medical Systems, Inc., Oro Valley, AZ). Specimens were incubated with the primary antibody, followed by detection with OptiView DAB (ref. 760-700, Ventana Medical Systems, Inc.), UltraView-DAB (ref. 760-500, Ventana Medical Systems, Inc.), or UltraView-AP (ref. 760-501, Ventana Medical Systems, Inc.) with amplification (amplification kit ref: 760-080 or OptiView amplification kit ref: 760-099, Ventana Medical Systems, Inc.). Next, the specimens were counterstained with hematoxylin II (ref: 790-2208, Ventana Medical Systems, Inc.) and coverslipped.
Each slide contained a positive control. All stains were performed on the Ventana BenchMark Ultra (Ventana Medical Systems, Inc.). Primary antibodies, detection, and amplification methods used are mentioned in Supplementary Table 1.

Belderbos R.A., Maat A.P., Baart S.J., Madsen E.V., Bogers A.J., Cornelissen R., Aerts J.G., Mahtab E.A, & von der Thüsen J.H. (2021). Ki67 (MIB-1) as a Prognostic Marker for Clinical Decision Making Before Extended Pleurectomy Decortication in Malignant Pleural Mesothelioma. JTO Clinical and Research Reports, 2(4), 100155.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!